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While dopamine affects fundamental brain processes such asmovement control, emotional responses, addiction, and pain, the roles for
this neurotransmitter in regulating wakefulness and sleep are incompletely understood. Genetically modified animal models with re-
duced dopamine clearance exhibit hypersensitivity to caffeine, reduced-responsiveness to modafinil, and increased homeostatic re-
sponse to prolonged wakefulness when compared with wild-type animals. Here we studied sleep–wake regulation in humans and
combined pharmacogenetic and neurophysiologic methods to analyze the effects of the 3-UTR variable-number-tandem-repeat poly-
morphism of the gene (DAT1, SLC6A3) encoding dopamine transporter (DAT). Previous research demonstrated that healthy homozy-
gous 10-repeat (10R/10R) allele carriers of this genetic variant have reduced striatal DAT protein expression when compared with
9-repeat (9R) allele carriers. Objective and subjective estimates of caffeine sensitivity were higher in 10R allele homozygotes than in
carriers of the 9R allele.Moreover, caffeine andmodafinil affected wakefulness-induced changes in functional bands (delta, sigma, beta)
of rhythmic brain activity in wakefulness and sleep in a DAT1 genotype-dependent manner. Finally, the sleep deprivation-induced
increase in well established neurophysiologic markers of sleep homeostasis, including slow-wave sleep, electroencephalographic slow-
wave activity (0.5–4.5 Hz), and number of low-frequency (0.5–2.0 Hz) oscillations in non-rapid-eye-movement sleep, was significantly
larger in the 10R/10R genotype than in the 9R allele carriers ofDAT1. Together, the data suggest that the dopamine transporter contrib-
utes to homeostatic sleep–wake regulation in humans.
Introduction
The concept of sleep homeostasis predicts that increased sleep
need after prolonged wakefulness results in compensatory changes
in sleep duration and intensity in recovery sleep (Borbe´ly, 1982).
Slow-wave sleep (SWS); electroencephalogram (EEG) slow-wave
activity (SWA; power within 0.5–4.5 Hz); and number, ampli-
tude, and slope of individual slow (0.5–2.0Hz) waves in non-rapid-
eye-movement (NREM) sleep are robust physiological markers of
sleep homeostasis (Borbe´ly, 1982; Achermann and Borbe´ly, 2011).
The neurochemical and molecular bases underlying this fun-
damental regulatory mechanism of wakefulness and sleep are
poorly understood.
Accumulating evidence suggests the contribution of dopa-
mine to sleep homeostasis. Mutant flies (Datlo) with reduced do-
pamine acetyltransferase activity exhibit a greater sleep rebound
after prolonged wakefulness than wild-type controls (Greenspan
et al., 2001). Furthermore, Drosophila and mouse mutants lack-
ing functional dopamine transporters (DAT) exhibit prolonged
wakefulness and shortened sleep (Giros et al., 1996; Wisor et al.,
2001; Kume et al., 2005; Wu et al., 2008). The DAT is highly
expressed in striatum (Lewis et al., 2001), where it is responsible
for re-uptake of dopamine (Giros andCaron, 1993) and constitutes
the limitingmechanism of dopaminergic neurotransmission (Jones
et al., 1998; Benoit-Marand et al., 2000). Dat knock-out mice are
hypersensitive to caffeine (Wisor et al., 2001), consistent with the
notion that dopaminergic mechanisms importantly contribute to
wake-promotion of this stimulant (Boutrel and Koob, 2004; An-
dretic et al., 2008).
In humans, the roles for dopamine in sleep–wake regula-
tion are not well understood. Patients with Parkinson’s disease
typically present with disturbed sleep and daytime sleepiness
(Park and Stacy, 2011), whereas in healthy volunteers L-dopa
andD2/D3 receptor agonists may reduce vigilance and increase
sleepiness (Andreu et al., 1999; Micallef et al., 2009). Caffeine
increases striatal dopamine (Kaasinen et al., 2004). The effects
of this xanthine on sleep are modulated by genetic variants of
adenosine A2A receptors (Re´tey et al., 2007; Bodenmann et al.,
2012). Interestingly, these receptors are also primarily ex-
pressed in striatum and functionally interact with D1/D2 re-
ceptors (Lovinger, 2010).
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Thewake-promoting agent,modafinil, binds toDAT (Mignot
et al., 1994; Volkow et al., 2009) and is ineffective in Dat knock-
out mice (Wisor et al., 2001). Previous research suggests that this
compounddoes not interferewith sleep homeostasis (Kopp et al.,
2002; Bodenmann et al., 2009; Bodenmann and Landolt, 2010).
Nevertheless, based on preclinical evidence for amodulatory role
of dopamine in sleep homeostasis (Greenspan et al., 2001), we
expected that a variable-number-of-tandem-repeat (VNTR)
polymorphism (SNP-ID: rs28363170) of the DAT gene (DAT1,
SLC6A3) may affect the homeostatic response to sleep loss in
healthy adults. Nine or 10 repeats of a 40 bp sequence of this
genetic variant are most common (Vandenbergh et al., 1992).
Ten-repeat (10R) allele homozygotes have 15–20% reducedDAT
availability in the striatum compared with heterozygous and ho-
mozygous 9-repeat (9R) allele carriers (Costa et al., 2011; Spencer
et al., 2013). Given the findings in Datlo flies and Dat knock-out
mice, we hypothesized that neurophysiologic markers of sleep
homeostasis are more strongly affected by caffeine and sleep de-
privation in 10R/10R homozygotes than in 9R allele carriers.
Materials andMethods
Study participants and genotyping. The study protocol was approved by
the ethics committee of the Canton of Zu¨rich for research on human
subjects. Written informed consent was obtained from all participants
before the experiments, as required according to the principles in the
Declaration of Helsinki. All subjects received financial compensation for
their participation.
A total of 504 healthy volunteers (374 males, 130 females) between 18
and 35 years of age were investigated. They were interested in participat-
ing in sleep studies and provided 3 ml of fresh EDTA blood (n  472;
Wizard Genomic DNA Purification Kit; Promega) or saliva (n  32;
NucleoSpin Blood Kit, Marchery-Nagel AG) for isolation of genomic
DNA. Their genotype of the rs28363170 polymorphism of DAT1 was
determined by allele-specific PCR on an MJ Research PTC-225 thermal
cycler (MJ Research/Bio-Rad) at an annealing temperature of 67°C. For-
ward primer, 5-tgtggtgtagggaacggcctga-3, and reverse primer, 5-
cttcctggaggtcacggctcaa-3, with HOT FIREPol DNA polymerase was
used. The 430–480 bp PCR products were analyzed by agarose gel elec-
trophoresis. All analyses were replicated at least once for independent
confirmation. In total, 258 individuals (69 females) were 10R/10R allele
carriers, 204 (56 females) were heterozygous 9R/10R allele carriers, and
23 (4 females) were homozygous 9R/9R allele carriers. Nineteen carriers
of rare DAT1 alleles (3.8%) were excluded from the analyses. The allele
frequencies in our sample were consistent with previous findings in a
Caucasian population, yet may differ considerably from other world
populations (Mitchell et al., 2000).
To examine a possible impact of the DAT1 polymorphism on
sleep–wake regulation, sleep and sleep EEG recordings before and
after sleep deprivation were analyzed in a subset of 57 genotyped,
right-handed subjects (46 men and 11 women) who previously com-
pleted sleep studies in our laboratory. Given the low number of 9R/9R
homozygotes (n  3), homozygous and heterozygous (9R/10R) 9R
allele carriers (n  27) were grouped and compared with 10R/10R
homozygotes (n 30). Based on previous research, these two groups
presumably differ in DAT protein expression (Jacobsen et al., 2000;
van Dyck et al., 2005; van de Giessen et al., 2009; Costa et al., 2011;
Spencer et al., 2013). They accurately matched in age, body mass
index, habitual sleep duration, and daily caffeine and alcohol con-
sumption, as well as in the distribution of distinct COMT and aden-
osine A2A receptor (ADORA2A) genotypes (Table 1). Control of these
gene variants is important because previous work revealed that they
associate with individual differences in neurobehavioral performance
during prolonged waking and the behavioral and neurophysiological
effects of modafinil and caffeine (Bodenmann and Landolt, 2010;
Bodenmann et al., 2012).
All volunteers reported to be good sleepers, adhering to regular
bedtimes, to be in good physical health, and to have a medical history
free of neurological and psychiatric disorders. Two months before
enrollment, subjects stated not to have consumed any medication or
illicit drugs, not to have passed through time zones, and to consume
moderate amounts of caffeine and alcohol. To check for potential
undiagnosed sleep disorders or low sleep efficiency (85%), they
underwent a screening night in the sleep laboratory before study
inclusion. Two weeks before study initiation, participants were in-
structed to wear a wrist activity monitor on their nondominant arm,
to fill out a sleep–wake diary, and to completely refrain from intake of
caffeine. The final 3 d before the start of the experiment, they were
required to strictly maintain regular bedtimes (8 h sleep) and to ab-
stain from alcohol.
Sleep deprivation protocol. The sleep deprivation study involved
either one (n  19; 12 females, 7 males) or two (n  38; all males)
experimental blocks. Three participants completing only one block
were moderate smokers (10 cigarettes per day). Each experimental
block consisted of three nocturnal sleep recordings, all starting either
at 23:00 or 00:00, divided into 8 h adaptation and baseline nights, 40 h
of constantly supervised prolonged wakefulness, and concluded by a
10 h recovery night.
Subjects completing two experimental blocks were administered after
11 (at 19:00) and 23 h (at 07:00) of prolonged wakefulness 2 200mg of
caffeine and placebo (n 16; 10R/10R: n 9; 9R/10R: n 7), or 2 100
mg of modafinil and placebo (n 22; 10R/10R: n 11; 9R/10R: n 8,
9R/9R: n 3), in randomized, double-blind cross-over fashion.
All-night polysomnography. Sleep was polysomnographically quanti-
fied during all experimental nights. The EEG, electro-oculogram, sub-
mental electromyogram, and electrocardiogram were recorded using
polygraphic amplifiers (PSA24; Braintronics; Re´tey et al., 2006) or Arti-
san, Micromed (Bachmann et al., 2012) as follows. For 16 subjects re-
corded via PSA24 amplifiers, analog EEG data were bandpass filtered
(3 dB at 0.16 Hz; 3 dB at 102 Hz) and sampled at 512 Hz, then
digitally low-pass filtered (3 dB at 49 Hz) and stored with a resolution
of 128 Hz. For 41 subjects recorded via Artisan amplifiers, analog EEG
data were bandpass filtered (3 dB at 0.15 Hz; 3 dB at 67.2 Hz),
sampled, and stored with a resolution of 256 Hz. The EEG data of deri-
vation C3A2 were analyzed.
Sleep stages were visually scored in 20 s epochs according to standard
criteria (Rechtschaffen and Kales, 1968). Four second EEG spectra (fast
Fourier transform routine, Hanning window, 0.25 Hz resolution) were
calculated using MATLAB (MathWorks), averaged over five consecu-
tive 4 s epochs, and matched with scored sleep stages. Arousal- and
movement-related artifacts were semi-automatically identified and ex-
cluded. All-night power spectra between 0 and 20 Hz represent the aver-
Table 1. Demographics
10R/10R 9R allele carriers p value
COMT genotype (rs4680; G/A) 1.00
G/G (Val/Val) 13 11
G/A (Val/Met) 8 7
A/A (Met/Met) 9 9
ADORA2A genotype (rs575876; T/C) 0.15
T/T 8 4
C/T 16 11
C/C 6 12
Sex ratio (% females) 20.0 18.5 1.00
Age (years) 24.6 0.6 24.7 0.6 0.89
Body mass index (kg/m 2) 22.8 0.4 22.0 0.3 0.09
Habitual sleep duration (hours) 7.3 0.2 7.4 0.2 0.79
Caffeine consumption (mg/d) 139.0 26.0 103.6 22.5 0.31
Alcohol consumption (drinks/week) 3.2 0.6 2.8 0.4 0.60
Trait Anxiety (STAI) 39.3 1.5 36.9 1.5 0.26
Daytime Sleepiness (ESS) 7.2 0.5 7.0 0.5 0.81
Symbols of the National Center for Biotechnology Information indicate genes encoding dopamine transporter
(DAT1), catechol-O-methyl-transferase (COMT), and adenosine A2A receptor (ADORA2A). The distributions of COMT
and ADORA2A genotypes and the sex ratio in 10R/10R and 9R allele carriers of DAT1 did not differ between the two
groups (Fisher’s Exact Tests). Other variables representmean SEM, based on validated self-report questionnaires;
p-values refer to two-tailed Student’s t test. STAI, State-trait anxiety inventory (Spielberger et al., 1970); ESS,
Epworth Sleepiness Scale (Johns, 1991).
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age of all artifact-free 20 s values in NREM sleep (stages 1–4). In the
recovery nights, data analysis was restricted to the first 8 h of the 10 h
sleep recordings. All-night and episodic EEG power values in NREM
sleep were standardized in each individual to the corresponding all-night
power of the baseline night.
To analyze the effects of caffeine,modafinil,DAT1 genotype, and sleep
deprivation on individual EEG slow waves, an algorithm previously de-
scribed (Bersagliere and Achermann, 2010) was applied. Data sampled
with 256 Hz were downsampled to 128 Hz using the MATLAB function
decimate (MathWorks). To ensure reliable wave detection, the EEG
(0.5–2.0 Hz) was bandpass filtered (third-order Chebyshev type II high-
pass filter; –3 dB at 0.4 Hz; sixth-order Chebyshev type II low-pass filter,
–3 dB at 2.3 Hz). Filters were applied both in forward and reverse direc-
tions, to prevent phase distortion. Individual positive and negative half-
waves with an amplitude of 37.5 V (75 V peak to peak;
Rechtschaffen and Kales, 1968) were defined as positive or negative de-
flections between consecutive zero-line crossings. Waves were analyzed
in steps of 0.1 Hz. The amplitude was defined as the local maximum or
minimum between two consecutive zero-line crossings, whereas the
slope was defined as the amplitude of the peak or the trough, divided by
the time from the previous zero-line crossing (initial mean slope). The
number of waves included all detected waves that fulfilled the 37.5
V-amplitude criterion.
Waking EEG recordings. At 3 h intervals during the 40 h prolonged
wakefulness, standardized waking EEG recordings were performed. At
least 1 h before each recording, subjects had to stay in the laboratory
(constant temperature: 1921°C; light intensity: 150 lux). Fifteen
minutes before each recording, they calmly stayed on their own in their
bedrooms. The study participantswere instructed to comfortably relax in
a chair, and to place their chin on an individually adjusted chinrest. An
initial 3 min recording period with eyes closed was followed by a 5 min
period with eyes open, while subjects fixated a black dot attached to the
wall. Artifacts in all derivations were visually identified and excluded.
Power spectra (C3A2 derivation) of artifact-free, 2 s epochs (50% over-
lap, Hanning window, frequency resolution 0.5 Hz) were computed and
analyzed between 0 and 25 Hz. To minimize interindividual differences
in absolute power and to compensate for circadian effects, spectra were
standardized in each individual to the mean of the first four sessions
during extended waking.
Statistical analyses. All statistical analyses were performed with SAS
9.1.3 software (SAS Institute). In 10R/10R and 9R allele carriers ofDAT1,
the effects of caffeine and modafinil on waking EEG, sleep architecture,
EEG spectra, and individual EEG slow half-waves, as well as the sleep
deprivation-induced rebound in these variables were analyzed. Two- and
three-way mixed-model ANOVA for repeated measures (PROC
MIXED) with the between-subjects factor “genotype” (10R/10R vs 9R
allele carriers) and the within-subjects factors “treatment” (caffeine/
modafinil vs placebo), “NREM sleep episode” (1–4), “condition” (base-
line vs sleep deprivation/recovery), and “frequency bin” (0.5, 0.25, or 0.1
Hz resolution)were performed. The significance level was set at 0.05.
Only significant effects and interactions are mentioned, unless otherwise
specified. Post hoc analyses were only performed when the respective
main effect and/or interaction of the ANOVA were significant.
Figure 1. DAT1 genotype modulates the effects of caffeine (10R/10R: n 9 [black diamonds]; 9R allele carriers: n 7 [gray diamonds]), and modafinil (10R/10R: n 11 [black squares]; 9R
allele carriers: n 11 [gray squares]) intake during sleep deprivation on EEG activity in wakefulness (eyes open) and NREM sleep. A, B, Effects of caffeine. C, D, Effects of modafinil. Left, Relative
power values in the waking EEG recording sessions at 08:00, 11:00, 14:00, and 17:00 on day 2 of prolonged wakefulness after caffeine (2 200 mg) and modafinil (2 100 mg) were expressed
as a percentage of the corresponding values after placebo (horizontal dashed lines at 100%). Caffeine reduced power in many bins14.5 Hz, and increased power in high-beta (21–24 Hz)
frequencies (in 10R/10R carriers only). Modafinil reduced theta (5.5–7 Hz) activity and increased alpha (11–12 Hz) activity. Right, Standardized all-night power values in NREM sleep (stages 1–4)
after caffeine (2 200mg) andmodafinil (2 100mg) intakewere expressed as a percentage of the corresponding values after placebo (horizontal dashed lines at 100%). Caffeine reduced 1.5–2
Hz activity. Modafinil increased power inmany bins in the alpha/beta range (11.25–20 Hz), primarily in 9R carriers of DAT1. Mean SEM consecutive 0.5 Hz (wakefulness) or 0.25 Hz (NREM sleep)
frequency bins are plotted. Gray diamonds indicate a significant genotype treatment interaction ( pall 0.05) of a two-waymixed-model ANOVAwith the between-subjects factor genotype and
the within-subjects factor treatment (caffeine or modafinil). Upward and downward black triangles indicate a significant main effect of treatment ( pall 0.05). Note the different scales of y- and
x-axes in wakefulness and NREM sleep.
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Results
DAT1 genotype modulates effects of caffeine on low-
frequency brain oscillations in wakefulness and sleep
To investigate a possible role for DAT in sleep–wake regulation, the
combined effects of sleep deprivation and caffeine and modafinil
were examined in adataset of 57healthy adult 10R/10Rand9Rallele
carriers (Table 1). Sleep architecture in baseline, and the behavioral
effects of prolonged wakefulness (i.e., increased sleepiness and im-
paired performance on the psychomotor vigilance task) were highly
similar in the two genotypes (data not shown).
Caffeine intake during sleep deprivation affected EEG low-
frequency activity in wakefulness and sleep. The stimulant reduced
waking EEG activity in delta (2Hz), theta (4–7Hz), alpha (8–9.5
Hz), and low-beta (13–14.5 Hz) frequencies (treatment: F(1,14) 
4.61; pall  0.05; Fig. 1A). Moreover, it enhanced beta (21–24 Hz;
genotype treatment interaction:F(1,14)4.25;pall0.05) activity
in 10R/10R carriers (caffeine: 151.6 9.5%; placebo: 109.3 9.7%;
t(8)2.40,p0.05; two-tailed,paired t test), yetnot in9Rcarriers
(caffeine: 103.9  11.4%; placebo: 127.2  4.5%; t(6)  1.51, p 	
0.18; two-tailed, paired t test). This differencemay reflect the higher
subjective caffeine sensitivity in 10R allele carriers when compared
with 9R allele carriers ofDAT1. The proportion of sensitive individ-
uals among all genotyped individuals (n 485) as assessed with the
question “Do you consider yourself as caffeine sensitive?” (yes/no)
differed among the genotypes (p  0.008, Fisher’s exact test). It
equaled 38.8% (100/258) in 10R/10R allele carriers, 33.3% (68/204)
in 9R/10R allele carriers, and 8.7% (2/23) in 9R/9R allele carriers
(online supporting supplemental information, Fig. S1).
During recovery sleep, caffeine consistently reduced EEG low-
delta (1.5–2.0Hz) activity inNREM sleep (Fig. 1B). Close inspec-
tion of the data indicated that this effect of caffeine may differ
between 10R/10R and 9R allele carriers of DAT1. To further ex-
amine this notion, individual sleep slow waves were analyzed.
DAT1 genotype modulates the effects of caffeine on
individual slow waves in NREM sleep
Sleep deprivation markedly increased number, amplitude, and
slope of individual, positive and negative slow half-waves in re-
Figure 2. DAT1 genotype modulates the effects of caffeine intake during sleep deprivation on positive (left) and negative (right) EEG slow half-waves in NREM sleep. Number (A, B), amplitude
(C, D), and slope (E, F ) in 10R/10R (black diamonds, n 9) and 9R allele carrier (gray diamonds, n 7) genotypes of DAT1 are illustrated. Absolute data were normalized to the corresponding
recovery night after intake of placebo (horizontal dashed line at 100%) and used for analyses; p values refer to the factor genotype of a two-way, mixed-model ANOVA with the between-subject
factor genotype and the within-subject factor frequency bin. Error bars indicate SEM.
Holst et al. • DAT1 Genotype, Caffeine, and Sleep Homeostasis J. Neurosci., January 8, 2014 • 34(2):566–573 • 569
covery sleep when compared with baseline sleep (condition:
F(1,55)	 93.7; pall 0.0001). Intake of caffeine during prolonged
wakefulness reduced all these features of negative half-waves, as
well as number and amplitude of positive half-waves in 10R/10R
carriers ofDAT1 (Fig. 2). In contrast, the stimulant did not affect
the characteristics of positive and negative slow half-waves in 9R
allele carriers.
Modafinil does not affect low-frequency brain oscillations in
wakefulness and sleep
Intake of modafinil during prolonged wakefulness reduced wak-
ing EEG activity in the 5.5–7Hz range and elevated activity in the
11–12 Hz band when compared with placebo (treatment: F(1,20)
 5.13; pall 0.05; Fig. 1C). In the recovery night, modafinil did
not affect low-frequency EEG activity in NREM sleep (Fig. 1D),
or the number, amplitude, and slope of EEG slow half-waves
(data not shown). Nevertheless, the stimulant increased power in
alpha (11.25–12.5 Hz) and beta (13.5–20 Hz) frequencies in
NREMsleep, primarily in 9R carriers ofDAT1 (genotype treat-
ment: F(1,20) 4.49; pall 0.05; Fig. 1D).
DAT1 genotype modulates the rebound in SWS and EEG
SWA after sleep deprivation
Research in animals and humans demonstrated that caffeine at-
tenuates EEG markers of sleep homeostasis after prolonged
wakefulness (Schwierin et al., 1996; Landolt et al., 2004; Re´tey et
al., 2006; Landolt, 2008). Because the effects of caffeine in NREM
sleep reflected genotype-dependent changes in EEG slow oscilla-
tions, the repercussions of prolonged wakefulness on these neu-
rophysiologic markers of sleep homeostasis were examined in
10R/10R and 9R allele carriers ofDAT1. In both genotypes, sleep
deprivation increased sleep efficiency and the duration of NREM
sleep, and shortened sleep latency, sleep stages 1 and 2, REM
sleep, and wakefulness after sleep onset in the recovery night
when compared with the baseline night (online supporting sup-
plemental information, Table S1). Nevertheless, the rebound in
deep SWSwas strikingly different between 10R/10R and 9R allele
carriers of DAT1 (condition  genotype interaction: F(1,55) 
10.8, p  0.002; condition: F(1,55)  644.1, p  0.0001). More
specifically, it was 15 min longer in 10R/10R than in 9R allele
carriers (t(55)3.32, p 0.002; two-tailed t test; Fig. 3, inset).
This difference was accompanied by a slightly more pronounced
reduction in stage 2 sleep in the 10R/10R genotype (21.6 4.8
min) than in the 9R allele carriers (9.8 4.8 min; genotype
condition: F(1,55) 3.0, p 0.09).
In baseline and recovery nights, EEG SWA (0.5–4.5Hz range)
decayed exponentially across consecutive NREM sleep episodes,
reflecting the dissipation of homeostatically regulated NREM
sleep pressure. The time constants of the decay (d) quantified by
the method proposed by Rusterholz et al. (2010) were similar in
both nights and genotypes (online supporting supplemental in-
formation, Fig. S2). Interestingly, however, the rebound in SWA
in the recovery night compared with the baseline night was larger
in 10R/10R than in 9R allele carriers ofDAT1 (genotype: F(1,55)
4.8, p 0.03; NREM sleep episode: F(3,165) 372.7, p 0.0001;
Fig. 3). The analyses of individual EEG slow waves revealed that
this difference reflected a more pronounced increase in 10R/10R
than in 9R allele genotypes in the number of positive and negative
half-waves after sleep deprivation (Fig. 4). In contrast, the
changes in amplitudes and slopes of individual slow waves in
NREM sleep did not differ between the genotypes.
Discussion
Ample evidence suggests that homozygous 10R/10R allele carri-
ers of the 3-VNTR polymorphism of the DAT1 gene have re-
duced DAT protein expression in the striatum when compared
with 9R allele carriers (Heinz et al., 2000; Jacobsen et al., 2000;
Fuke et al., 2001; VanNess et al., 2005; van Dyck et al., 2005; van
de Giessen et al., 2009; Costa et al., 2011; Spencer et al., 2013).
Based on preclinical studies inmutant animals (Giros et al., 1996;
Greenspan et al., 2001; Wisor et al., 2001; Kume et al., 2005;
Andretic et al., 2008; Wu et al., 2008) as well as molecular brain
imaging data in humans (Volkow et al., 2012), we hypothesized
that this “experiment of nature” is associated with individual
differences in sleep–wake regulation. Our data revealed not only
pharmacogenetic support for this hypothesis, but also demon-
strated that healthy carriers of the 10R/10R genotype show in-
creased rebound in SWS, SWA, and number of slow EEG waves
after sleep deprivation when compared with 9R allele carriers.
These findings suggest an increased homeostatic response to
sleep deprivation in 10R/10R homozygotes when compared with
9R allele carriers of DAT1.
Apart from being an adenosine receptor antagonist (Fred-
holm et al., 1999), the stimulant action of caffeine has been sug-
gested to also rely on the dopaminergic system, and to depend on
DAT expression (Wisor et al., 2001; Boutrel and Koob, 2004;
Fisone et al., 2004; Andretic et al., 2008). Our study showed that
caffeine administered during sleep deprivation increased EEG
21–24 Hz activity in wakefulness in 10R/10R homozygotes, yet
not in 9R allele carriers (Fig. 1A). Elevated EEG -activity in
waking was also reported after oral intake of the DAT blocker,
cocaine, which may reflect increased brain arousal (Herning et
al., 1985). Together with observations in mice (Wisor et al.,
2001), the data suggest that reduced expression of DAT, such as
in 10R/10R allele carriers ofDAT1 and inDat knock-out animals,
is associated with elevated sensitivity to the stimulant action of
the adenosine receptor antagonist caffeine.
The present study revealed that this conclusionmay also apply
to the effects of caffeine on neurophysiologic markers of sleep
homeostasis. Intake of the stimulant during prolonged wakeful-
ness reduced EEG low-frequency activity in the delta (wakeful-
Figure 3. DAT1 genotype modulates the rebound in SWS and EEG SWA (0.5–4.5 Hz) in the
recoverynight after sleepdeprivation. Inset, Data reflect themeanabsolute all-night increase in
SWS after sleep deprivationwhen comparedwith baseline, in 10R/10R (black bar, n 30) and
9R allele carrier (gray bar, n 27) genotypes of DAT1. *p 0.002 (two-tailed t test). Main
figure, Mean relative SWA, expressed as a percentage of the all-night value in baseline (hori-
zontal dashed line at 100%). Values in 10R/10R (black dots, n 30) and 9R allele carriers (gray
dots, n 27) across the first four NREM sleep episodes were plotted at the mean episode
midpoints relative to sleep onset. Error bars indicate SEM.
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ness: 0–2 Hz; NREM sleep: 1.5–2 Hz) and theta (wakefulness:
4–9.5 Hz) ranges in vigilance state-specific manner (Fig. 1A,B).
In contrast, administration of modafinil, which reduces DAT-
mediated re-uptake of dopamine in animals (Mignot et al., 1994)
and humans (Volkow et al., 2009), decreased theta power (5.5–7
Hz) in waking, yet did not affect delta activity in NREM sleep
(Fig. 1C,D). These findings corroborate the previous conclusion
that intake of caffeine and modafinil during sleep deprivation
differentially affects EEG markers of sleep homeostasis in wake-
fulness and sleep (Bodenmann et al., 2009; Bodenmann and Lan-
dolt, 2010). The present refined analyses revealed that caffeine
reduced number, amplitude, and slope of sleep slow waves in a
DAT1 genotype-dependent manner. This finding suggests that
the interference of caffeine with neurophysiologic markers of
sleep homeostasis not only relies on adenosinergic mechanisms
but also involves dopaminergic processes. Furthermore, adenos-
inergic–dopaminergic interactions appear necessary for the
stimulant-induced suppression of low-frequency brain oscilla-
tions reflecting sleep homeostasis. Supporting this notion, ge-
netic variation ofADORA2A alsomodulates the effects of caffeine
on SWA after sleep deprivation (Bodenmann et al., 2012).
A modulatory role for dopamine in the homeostatic response
to sleep deprivationwas previously observed in fruit flies carrying
the Datlo mutation (Greenspan et al., 2001). This mutation re-
sults in pronounced reduction in enzymatic clearance of dopa-
mine (Greenspan et al., 2001). Bothmutant and control flies slept
similarly in baseline. Following 12 h of sleep deprivation, how-
ever,mutant flies displayed a greater sleep rebound than controls,
and the homeostatic response was even larger in Datlo/Df flies
who exhibit a complete removal of the gene encoding dopamine
acetyltransferase (Greenspan et al., 2001). In accordance with
these studies in flies, we and others (Guindalini et al., 2010) in-
vestigating healthy humans found no impact of theDAT1VNTR
on sleep architecture in baseline. Nevertheless, a challenge of
sleep homeostasis by sleep deprivation induced a larger rebound
in SWS, SWA, and the number of individual slow half-waves in
NREM sleep in 10R/10R allele homozygotes than in 9R allele
carriers. Thus, our fine-grained EEG analyses indicate for the first
time in humans that DAT contributes to homeostatic sleep–wake
regulation.
Individual low-frequency EEG oscillations in the 0.5–2 Hz
range in NREM sleep are homeostatically regulated (Bersagliere
Figure 4. DAT1 genotypemodulates the effects of sleep deprivation on positive (left) and negative (right) EEG slow half-waves in NREM sleep. Number (A, B), amplitude (C,D), and slope (E, F )
in 10R/10R (black dots, n 30) and 9R allele carrier (gray dots, n 27) genotypes of DAT1 are illustrated. Normalized data relative to the corresponding all-night baseline values ( 100%)were
analyzed;p values refer to the factor genotype of a two-way,mixed-model ANOVAwith thebetween-subject factor genotype and thewithin-subject factor frequency bin. Error bars indicate SEM.
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andAchermann, 2010; online supporting supplemental informa-
tion, Fig. S3). They are thought to reflect, at the cellular level, the
degree of synchrony in the occurrence of up- and down-states in
the membrane potential of cortical neurons (Mukovski et al.,
2007; Vyazovskiy et al., 2009). Sleep loss increased in a genotype-
dependent manner the number of slow waves, but not their am-
plitude and slope (Fig. 4). Together with the data presented in
Figure 3, this observation suggests that DAT1modulates the du-
ration of the sleep deprivation-induced rebound in SWS, rather
than the absolute level of SWA that reflects the synchrony of up-
and down-states in cortical networks. A possible underlying
mechanismmay be related to retinoic acid receptors, which affect
dopamine signaling in themesolimbic system (Krezel et al., 1998)
and strongly contribute to EEG slow-wave oscillations during
sleep in mice (Maret et al., 2005).
Not only preclinical data, but also clinical observations, sup-
port a role for striatal dopamine in sleep–wake regulation. Pro-
nounced hyperactivity, caffeine hypersensitivity, and reduced
sleep are typically observed in Dat knock-out animals (Giros et
al., 1996;Wisor et al., 2001; Kume et al., 2005;Wu et al., 2008). In
contrast, impaired dopaminergic neurotransmission in the stria-
tum in patients with Parkinson’s disease is often accompanied by
severely disturbed sleep and disabling daytime sleepiness (Park
and Stacy, 2011). It is evident that our findings in healthy indi-
viduals with distinct DAT1 genotypes need to be treated with
caution when compared with sleep–wake changes in Dat knock-
out animals and in patients with neurodegenerative depletion of
dopamine. Nevertheless, the stronger response to caffeine and
the larger rebound in neurophysiologic markers of sleep homeo-
stasis after sleep deprivation are consistent with reduced DAT
expression and increased dopaminergic signaling in 10R/10R ho-
mozygotes than in 9R allele carriers. Thus, our study provides
novel physiological evidence for a functional effect of the com-
mon VNTR polymorphism of DAT1. Moreover, because the
DAT protein is primarily expressed in the striatum, it suggests a
specific role for striatal dopaminergic neurotransmission in sleep
homeostasis.
Notes
Supplemental material for this article is available at http://www.pharma.
uzh.ch/research/chronobiology/areas/psychopharmacology/DAT1_sleep_
homeostasis.pdf. The online supporting supplemental material (one table
and three figures) includes more detailed information on DAT1 genotype-
dependent subjective caffeine sensitivity, sleep architecture, analysis of the
individual positive and negative slow half-waves for absolute data, and for
the estimates of SWA decay time constants. This material has not been peer
reviewed.
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